1/1

Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration

dataset
posted on 27.02.2019 by Renata Portella Nunes, Flávio Eduardo Hirai, Letícia Fernandes Barroso, Emmerson Badaró, Eduardo Novais, Eduardo Buchele Rodrigues, Mauricio Maia, Octaviano Magalhães Jr., Michel Eid Farah

ABSTRACT Purpose: To study the efficacy and safety of treatments with ranibizumab and bevacizumab for exudative age-related macular degeneration. Methods: A parallel randomized clinical trial was conducted to compare the efficacy and safety of three regimens (bevacizumab every month, bevacizumab every 2 weeks, and ranibizumab every month), followed by as-needed retreatments, for 1 year, in previously untreated individuals with age-related macular degeneration. The primary outcome was change in visual acuity and in central macular thickness after 1 year of follow-up. Subjects were assigned randomly to one of the three groups in a 1:1:1 ratio, and investigators and examiners were blinded to the randomization results. Results: We included 15 patients in each group. After 1 year of follow-up, we found statistically significant improvements in visual acuity and central macular thickness reduction in all groups. However, we found no statistically significant differences between the three groups. Conclusions: The bi-weekly follow-up was effective and we found no significant differences in efficacy or safety between the treatments with ranibizumab and bevacizumab.

History

Licence

Exports

Logo branding

Categories

Licence

Exports